AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06440837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB stress self-management health education
Description: The health education intervention program contains eight module topics: stress-related knowledge, the thinking and mentality under stress, social support, take care of your suffering, manage your difficult emotions, acceptance, embrace a better life, ending. One topic or session is delivered by weeks, each session lasting 30-40 minutes.
Study NCT06056154 — intervention group
Intervention type: DEVICE
Intervention: LIO ASQELIO TM monofocal QLIO130C
Description: Intraocular lens (IOL) implant. All patients will have been treated as per standard clinical practice.
Study NCT05092906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LP with complementary hypnoanalgesia
Description: The lumbar puncture technique will be identical to that of the group standard of care. Hypnosis will be performed by a health professional trained in this practice, in addition to the standard analgesic management.
Study NCT05092906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LP with standard of care
Description: The LP will be carried out according to the usual techniques without hypnosis.~Standard analgesic treatments will be used (except contraindications):~* EMLA (Lidocain+Prilocain) Cream/Patch~* Local anesthesia with lidocain chlorhydrate monohydrate 1% injectable~* Nitrous oxide
Study NCT04767230 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Intervention
Description: A heart-healthy diet + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil in adjunct to medical treatment for 3 months
Study NCT04767230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: A heart-healthy diet + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil in adjunct to medical treatment for 3 months
Study NCT05364944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 4126
Description: Intramuscular (IM) injection
Study NCT05364944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Description: Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration
Study NCT05364944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatuline ATG
Description: Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration
Study NCT06358638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is a cytotoxic monoclonal antibody (IgG1k) to CD38 and is commercially approved to treat multiple myeloma. CD38 is expressed on several types of blood cells including B-cells, antibody-secreting plasma blasts and plasma cells. As a result, it has been used to treat antibody-mediated diseases, including children with antibody-mediated cytopenias post-HCT.
Study NCT06358638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52.
Study NCT06358638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections as well as treat lymphangioleiomyomatosis and adults with perivascular epithelioid cell tumors.
Study NCT06358638 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total body irradiation is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell transplantation. The radiation is given in a low dose so that normal tissues can repair themselves.
Study NCT05334082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIFA 11+
Description: 15 progressive exercise drills for training preparation (warm-up)
Study NCT06417489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy
Description: Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid. The dose of metformin from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day.
Study NCT06417489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential treatment group
Description: Metformin, the dose from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day. After the fourth week of treatment, blood glucose levels were measured. For those whose blood glucose levels did not meet the standard (fasting blood glucose (FPG)\&gt;7mmol/L, postprandial blood glucose (PPG)\&gt;10mmol/L), 10 mg qd of Henagliflozin Prolinewas sequentially added. If the blood glucose levels did not meet the standard after 4 weeks of treatment (FPG\&gt;7mmol/L, PPG\&gt;10mmol/L), 100 mg qd of Ruigeliflozin was added
Study NCT04744597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real execution of Fitts's law tasks
Description: Children will be training Fitts's law tasks of different difficulties. Once each task will be solved, they will receive a new, more demanding task
Study NCT04744597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery of Fitts's law tasks
Description: Children will be training Fitts's law tasks of different difficulties, same as RE group but the exception of doing it mentally - motor imagery of Fitts's law tasks with eyes open.
Study NCT04744597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skip counting
Description: Children in SCg will silently count (one number per second) in the same working blocks as both experimental groups with a task of saying the number they reached during each block - control condition to keep them mentally active at very low mental engagement.
Study NCT04642261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10mg daily
Study NCT04642261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Identical in appearance to empagliflozin 10mg daily
Study NCT06454773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NCT/NFT
Description: extract from black pepper and hemp hull
Study NCT06454773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NCT/NFT
Description: extract from black pepper and hemp hull
Study NCT05021419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Streamlined protocol
Description: A streamlined drug protocol for optimizing heart failure medication
Study NCT05021419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Protocol
Description: Current standard optimization protocol as per NICE and ESC
Study NCT05848141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: This is a single site center-based supervised exercise intervention.
Study NCT04188665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MASL
Description: Patients treated with MASL lozenge
Study NCT04188665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients treated with placebo lozenge
Study NCT04903314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xcopri
Description: Xcopri will be administered orally not to exceed 400mg/day adult equivalent
Study NCT05454176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Libre 2
Description: The unblinded FreeStyle Libre 2 CGM will be placed every two weeks during months 0-12 for the CGM Cohort. Patients will be taught to insert the sensor themselves.~They will be given a 1 month supply at each monthly clinic visit and extra sensors in case a sensor falls out early. Patients will be given SMBG test strips to test capillary glucose for confirmation of any CGM glucose level \<=60mg/dl. They will keep track of the number of times this is necessary. Patients will return used sensors at each clinic visit. The study team will upload the data to a study website. Patients and care providers will have access to unblinded sensor data for clinical use.
Study NCT05454176 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Device for SMBG and Libre Pro
Description: A glucose meter and sufficient teststrips for fingerpoke glucose monitoring 3x/day will be provided for months 1-6. This is standard-of-care in Uganda. Glucose meters will be downloaded monthly in clinic as per usual clinical practice.~DeviceBlinded CGM device: Libre Pro (blinded data collection device, not an intervention) The blinded FreeStyle Libre Pro CGM will be inserted at each monthly clinic visit to provide control data, months 0-6 for the Control Group. They will return all used sensors at each clinic visit. The study team will upload the data to a study website. Neither patients nor the local research teams will have access to the blinded sensor data for clinical use until the end of months 0-6 so as not to influence standard diabetes management. They will instead rely on SMBG values as per usual routine.~After the first 6 months they will receive Libre 2 CGM systems as described above for the intervention group.
Study NCT04841304 — intervention group
Intervention type: DEVICE
Intervention: Loop recorder (Reveal LINQ, Medtronic)
Description: Implantation of a loop-recorder
Study NCT04841304 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Measurement (G6, Dexcom)
Description: Monitoring with a continuous glucose monitor
Study NCT06049043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention to Help Orient Men to Excel (IN-HOME)
Description: A multi module online training
Study NCT06049043 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AARP's English Care at Home resource webpage
Description: Caregiver information from the American Association of Retired Persons
Study NCT05352100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic Vibration Device
Description: The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
Study NCT06529406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: De-escalation of anti-CD20 treatment using ozanimod.
Study NCT05341843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: sertraline at the intended dose of 50 mg twice daily for 8 weeks.
Study NCT05341843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)
Study NCT05314166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: meditation practice
Description: Description: meditation practice
Study NCT05314166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meditation practice
Description: Description: meditation practice
Study NCT06200584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Antipsychotic Agent
Study NCT05178758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: Patients in the intervention (VR) group will receive a series of occupational and physical therapy rehabilitation training using the VR system. All training is consists of daily activities oriented by an occupational therapist, including grasp, grip, pinch, gross, and finger-hand coordination movement. Each training will take around 1 hour for one session per day 5 times per week over a maximum of 4 weeks. The training presented a one-on-one that allowed interaction between instructor (or VR system) and participant.
Study NCT02989012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GanMaoKangNing Granules
Description: 3 times a day, 2 bags each time.
Study NCT02989012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analogous Oseltamivir Phosphate Capsules
Description: 2 times a day,1 capsule each time.
Study NCT02989012 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oseltamivir Phosphate Capsules
Description: 2 times a day,1 capsule each time.
Study NCT02989012 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Analogous GanMaoKangNing Granules
Description: 3 times a day, 2 bags each time.
Study NCT06200584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Antipsychotic Agent
Study NCT06200584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Antipsychotic Agent
Study NCT06200584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone and Vitamin D and Vitamin E
Description: vitamin
Study NCT06200584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine and Vitamin D and Vitamin E
Description: vitamin and Antipsychotic agent
Study NCT06200584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine and Vitamin D and Vitamin E
Description: Vitamin and Antipsychotic agents
Study NCT05181579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuel therapy
Description: Some sacroiliac manipulation and mobilization techniques will be applied to patients by an experienced physiatrist. Patients in the manual therapy group will receive 5 sessions of sacroiliac joint manipulation once a week.
Study NCT05181579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint injection
Description: Corticosteroid (1 ml 40 mg methylprednisolone) and local anesthetic (1 ml 1% lidocaine) will be injected into the sacroiliac joint using a 22 G spinal needle, guided by fluoroscopy (C-arm fluoroscopy) by an experienced physiatrist. It will be applied just one time.
Study NCT05579080 — intervention group
Intervention type: DEVICE
Intervention: noninvasive ventilation
Description: The medical records whose patients used some type of non-invasive ventilatory device and devices that promote oxygen supplementation will be analyzed.
Study NCT06124118 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carboplatin chemotherapy
Description: Concurrent chemoradiation will be given per standard of care within 24 hours of initiation of standard of care radiation therapy. Treatment will include a paclitaxel/carboplatin chemotherapy regimen administered during the radiotherapy course (over 6-7 weeks).~Paclitaxel (50 mg/m2) will be administered intravenous over 1 hour followed by Carboplatin AUC = 2 mg/min/mL intravenous weekly (every 7 days ± 3 days) during radiotherapy 11, NCCN Non-small cell lung cancer guidelines 2023).~If a patient has a hypersensitivity reaction to weekly paclitaxel, weekly nab-paclitaxel is allowed to replace paclitaxel at the discretion of the treating medical oncologist 37. The recommended starting dose of weekly nab-paclitaxel is 40 mg/m2 to 50 mg/m2 38 39. Standard premedications with steroids, diphenhydramine, H2 receptor antagonist, and 5-HT3 receptor antagonist antiemetics must be administered per individual institutional guidelines.
Study NCT06124118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T (TTFields) System
Description: The NovoTTF-200T (TTFields) System is an investigational medical device delivering 150 kHz TTFields to the thorax for the treatment of patients at the age of 22 years or older. The device is a portable, battery operated system which delivers TTFields at 150 kHz to the thorax by means of insulated Transducer Arrays. The NovoTTF-200T produces electric forces intended to disrupt cancer cell division.~TTFields at 150 kHz to the thorax will be continuous for at least 11 hours a day on average, with a recommended duration of at least 18 hours a day. Subjects may take breaks for personal needs (e.g. showering, array exchange). TTFields may be continued as long as there is no disease progression per RECIST 1.1 or any of the treatment discontinuation conditions for subject withdrawal or termination.
Study NCT06124118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Consolidation Durvalumab will be given per standard of care and institutional guidelines every 4 weeks for up to 12 cycles. Refer to package insert for detailed pharmacologic, dosing, and safety information.
Study NCT06343558 — intervention group
Intervention type: OTHER
Intervention: Questionnaires, clinical scales and instrumental tests
Description: Questionnaires, clinical scales and instrumental tests to collect a wide range of balance and gait measures.
Study NCT04868461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Unheated Whey Protein (UWP) beverage
Description: The preload is made from whey protein powder. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
Study NCT04868461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Heated Whey Protein (HWP) beverage
Description: The preload is made from whey protein powder of 95% and it is heated for a certain amount of time. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
Study NCT04868461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein (Cas) beverage
Description: The preload is made from casein powder. The energy load of the preload is 105 kcal and has banana flavor and sweetener.
Study NCT04868461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: The preload is water acting as a control and contain the same banana flavor and sweetener to match the other three intervention - protein beverages.
Study NCT05939804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS will be applied to the experimental group on the 0th and 1st days after the surgery, and the pain assessment at the time of movement/rest before and after the procedure will be made by the researcher.
Study NCT06012578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISM5411
Description: Investigational Drug
Study NCT06012578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ISM5411 Matching Placebo
Study NCT06028646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Airway CT scan (DA-CT)
Description: Patient will be asked to perform movements during the scan.
Study NCT05840276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: The VISUAL-ICE uses a combination of argon and helium, to create a highly localized cold zone with temperatures between -20 and -100°C. A probe will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization to accurately determine the location of the nerve and to account for adjacent neurovascular structures and variations in anatomical structures. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Cryoneurolysis at each target site requires 2 freeze cycles with a duration of 3 mins, and with thaw cycles between 20-40 seconds.
Study NCT04630652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab-Rzaa
Description: Risankizumab at a dose of 150 mg with injections administered at baseline, week 4 and week 16 following FDA-approved dosage and time periods
Study NCT04630652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch biopsies of the skin at baseline visit
Description: Two 6 mm punch biopsies of the skin at baseline visit
Study NCT04630652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch biopsies of the skin at week 28 visit
Description: One 6 mm punch biopsy of the skin at week 28 visit
Study NCT06510517 — intervention group
Intervention type: OTHER
Intervention: Calculation of Mechanical Power.
Description: Total respiratory rate (RR). Positive end-expiratory pressure (PEEP) (the external or applied PEEP) recorded, not the total PEEP, or intrinsic PEEP. The plateau pressure (Pplat) was measured during an inspiratory pause on the ventilator. Peak inspiratory pressure (Ppeak) should be obtained while the patient is relaxed, not coughing or moving in bed. MP was calculated according to Gattinoni's simplified mechanical power equation as follows (3,8):~MP(J/min)=0.098×VT×RR×(Ppeak-0.5×ΔP).
Study NCT06510517 — intervention group
Intervention type: OTHER
Intervention: Measurement Diaphragmatic Excursion after first SBT
Description: Chest ultrasound to assess diaphragmatic excursion (DE(. M-mode was used to record the movement of the diaphragm during tidal breathing when the sampling line and diaphragm were as vertical as possible (not \< 70°). The data was measured from the first respiratory cycle at 0 min after SBT. The DE at 0 min, 5 min, and 30 min of SBT was respectively named as DE0, DE5, and DE30. The variation of right DE between each time point was named as ΔDE30-5 and ΔDE30-0. (7)